School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Comprehensive Cancer Centre, King's College London, London, United Kingdom.
Cancer Epidemiol Biomarkers Prev. 2021 Feb;30(2):245-247. doi: 10.1158/1055-9965.EPI-20-1538.
Self-sampling is poised to be a disruptor for cervical screening. So far, cancer screening has been a causality of COVID-19; however, the opposite may transpire for self-sampling. Self-sampling enables socially distanced cervical screening with an outreach that extends to underserved populations. As evidence mounts that self-sampling is noninferior to clinician-taken samples, the focus for self-sampling is now as a primary screening option for all women. Now, we have evidence from a modeling study (using Australia as an exemplar) to suggest that program effectiveness with primary self-sampling would be better than the current program, even if sensitivity is lower. Regulatory issues, suitable triage strategies, and clear communication about self-sampling are hurdles yet to be overcome. Nevertheless, existing evidence coupled with COVID-19 could be the tipping point for wider introduction of self-sampling..
自我采样有望成为宫颈癌筛查领域的颠覆者。到目前为止，癌症筛查一直是 COVID-19 的一个因果关系；然而，自我采样可能会出现相反的情况。自我采样可以实现社交距离的宫颈癌筛查，并扩大到服务不足的人群。随着越来越多的证据表明自我采样与临床医生采集的样本一样有效，自我采样现在作为所有女性的主要筛查选择。现在，我们有一项模型研究（以澳大利亚为例）的证据表明，即使敏感性较低，采用自我采样作为初级筛查的项目效果也将优于当前项目。监管问题、合适的分诊策略以及关于自我采样的清晰沟通仍然是需要克服的障碍。尽管如此，现有的证据加上 COVID-19 可能成为更广泛引入自我采样的转折点。
